<DOC>
	<DOCNO>NCT00353522</DOCNO>
	<brief_summary>This 2 arm study investigate efficacy safety RO4607381 patient coronary heart disease , CHD risk equivalent . After pre-randomization phase 5-12 week , patient randomize receive either RO4607381 ( 900mg po ) placebo po daily 24 week , concomitant atorvastatin 10-80mg daily , change cholesterol level lipoprotein metabolism measure . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study RO4607381 Patients With Coronary Heart Disease ( CHD ) CHD Risk Equivalent .</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Dalcetrapib</mesh_term>
	<criteria>adult patient , 1875 year age ; CHD CHD risk equivalent ; body weight &lt; 125kg visit 1. recent ( within 3 week screen ) clinically significant coronary event ; history statinassociated myopathy , intolerance statin ; history malignancy ( except curatively treat basal cell squamous cell cancer skin ) 3 year prior screen ; exposure RO4607381 past 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>